Literature DB >> 7088599

Kawasaki syndrome (the mucocutaneous lymph node syndrome).

M E Melish.   

Abstract

Kawasaki syndrome is a newly-recognized clinical entity characterized by multisystem involvement. It has an acute onset and triphasic clinical course. Although essentially a self-limiting disease, permanent vascular damage, especially involving the coronary arteries, may result. Pathologically, the disease is characterized by widespread vasculitis. There is a monomodal age distribution, with peak occurrence during the first two years of life and few affected over the age of 8 years. Males outnumber females 1.5:1; persons of Japanese extraction are overrepresented compared with other races, caucasians underrepresented. Community-wide epidemics have been reported from diverse locations but there is no evidence for direct person-to-person transmission. Etiology remains unknown. Therapy is supportive and should be directed at careful clinical evaluation for cardiovascular abnormalities and antiplatelet aggregation therapy.

Entities:  

Mesh:

Year:  1982        PMID: 7088599     DOI: 10.3928/0090-4481-19820201-10

Source DB:  PubMed          Journal:  Pediatr Ann        ISSN: 0090-4481            Impact factor:   1.132


  4 in total

1.  Arthritis in Kawasaki disease after responding to intravenous immunoglobulin treatment.

Authors:  Kyung-Yil Lee; Jin-Hee Oh; Ji-Whan Han; Joon-Sung Lee; Byung-Churl Lee
Journal:  Eur J Pediatr       Date:  2005-03-22       Impact factor: 3.183

2.  Recurrent Kawasaki disease.

Authors:  T A Vargo; J C Huhta; W H Moore; D A Person; M S Edwards
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655

3.  Kawasaki disease.

Authors:  E Larson
Journal:  West J Med       Date:  1984-06

Review 4.  Salicylate for the treatment of Kawasaki disease in children.

Authors:  J H Baumer; S J L Love; A Gupta; L C Haines; I Maconochie; J S Dua
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.